Mark C. Osterling

SJ-3366, a Unique and Highly Potent Nonnucleoside Reverse Transcriptase Inhibitor of Human Immunodeficiency Virus Type 1 (HIV-1) That Also Inhibits HIV-2

Robert W. Buckheit, Karen Watson, Valerie Fliakas-Boltz et al. · Antimicrobial Agents and Chemotherapy · 2001 · 77 citations · Full text

Unique Anti-Human Immunodeficiency Virus Activities of the Nonnucleoside Reverse Transcriptase Inhibitors Calanolide A, Costatolide, and Dihydrocostatolide

Robert W. Buckheit, E. Lucile White, Valerie Fliakas-Boltz et al. · Antimicrobial Agents and Chemotherapy · 1999 · 64 citations · Full text

Inhibition of Acute-, Latent-, and Chronic-Phase Human Immunodeficiency Virus Type 1 (HIV-1) Replication by a Bistriazoloacridone Analog That Selectively Inhibits HIV-1 Transcription

Jim A. Turpin, Robert W. Buckheit, David Derse et al. · Antimicrobial Agents and Chemotherapy · 1998 · 51 citations · Full text

Development of Hexadecyloxypropyl Tenofovir (CMX157) for Treatment of Infection Caused by Wild-Type and Nucleoside/Nucleotide-Resistant HIV

E. Randall Lanier, Roger G. Ptak, Bernhard Lampert et al. · Antimicrobial Agents and Chemotherapy · 2010 · 47 citations · Full text

Nucleoside/nucleotide-resistant Hiv, Hiv-1 Strains, Lower Cmx157 Ec +14

The Biological Effects of Structural Variation at the Meta Position of the Aromatic Rings and at the End of the Alkenyl Chain in the Alkenyldiarylmethane Series of Non-Nucleoside Reverse Transcriptase Inhibitors

Guozhang Xu, Mark Micklatcher, Maximilian A. Silvestri et al. · Journal of Medicinal Chemistry · 2001 · 30 citations · Full text

Bioorganic Chemistry, Structural Variation, Molecular Biology +18